Results 201 to 210 of about 23,326 (221)

Dupilumab

Reactions Weekly, 2021
  +5 more sources

Dupilumab

Reactions Weekly, 2019
  +6 more sources

Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials

Nature Medicine, 2023
Sonja Ständer, John T O'malley
exaly  

Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis

Journal of the American Academy of Dermatology, 2021
Anne-Sofie Halling, Nikolai Dyrberg Loft, Jonathan I Silverberg   +2 more
exaly  

Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation

Allergy: European Journal of Allergy and Clinical Immunology, 2020
Audrey Le Floc'h, Jeanne Allinne, Wei Keat Lim   +2 more
exaly  

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

Lancet, The, 2022
exaly  

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

Allergy: European Journal of Allergy and Clinical Immunology, 2020
Ioana Agache, Cezmi A Akdis, Mubeccel Akdis   +2 more
exaly  

Dupilumab’s duplicity

Journal of the American Academy of Dermatology
openaire   +2 more sources

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

Lancet, The, 2019
Claus Bachert, Martin Desrosiers, Peter Hellings   +2 more
exaly  

Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2022
exaly